To determine the diagnostic accuracy of the results of CSF tests compared to the gold standard PET imaging, the Munich researchers evaluated the data of over 400 patients with suspected Alzheimer's ...

Alector Therapeutics, working with AbbVie, was testing whether modulating immune cells in brain would slow Alzheimer's ...

TAMPA — November marks National Alzheimer’s Disease Awareness Month. According to the Alzheimer’s Association, nearly 7 ...

Cassava Sciences stock plummeted Monday — wiping out more than three-quarters of its value — after the company's Alzheimer's treatment failed in Phase 3 testing. Please watch the video at ...

As of September 30, 2024, Alector has $457.2 million in cash, cash equivalents, and investments, which the company continues to expect will provide runway through 2026. Alector plans to provide ...

Many of us wonder how to slow down or completely stop the progression of Alzheimer's disease. It is regarded as a ...

Researchers have uncovered how certain genetic mutations lead to unique spherical amyloid plaques in inherited forms of ...

A loss of brain volume associated with new immunotherapies for Alzheimer's disease may be caused by the removal of amyloid ...

A living will or living trust can also provide additional instructions for how your sister wishes her estate to be handled after her death. Crucially, a trust would help her executor, or the ...

Cassava Sciences on Monday said its experimental Alzheimer's disease drug did not meet the main or secondary goals in a late-stage study.

Cassava Sciences Inc.’s stock crated 85% in premarket trade Monday, after the clinical-stage biotech said a trial of a treatment for mild-to-moderate Alzheimer’s disease failed to meet its main goals.